Cardioprotection

Q: What is the clinical evidence from this study?

Study design: Review. Population: Anthracycline-induced cardiotoxicity. Intervention: Cardioprotective strategies (scheduling, cardioprotective agents, liposomal delivery).

Gill Levitt

doi:10.1046/j.1365-2141.1999.01544.x

September 1, 1999British Journal of Haematology

Cardioprotection

View at Publisher

Ask AI

Bookmark

Share

Why the study?

Do modified administration schedules, cardioprotective agents, or liposomal delivery reduce anthracycline-induced cardiotoxicity in patients receiving chemotherapy?

Key Points

The aim is to explore strategies to reduce cardiotoxicity associated with anthracycline treatment in malignancies.
Review of clinical and preclinical studies on anthracyclines and cardioprotective agents
Analysis of dosing methods, including liposomal delivery and scheduling
Assessment of histopathological changes and non-invasive monitoring techniques
Liposomal formulations showed reduced cardiotoxicity compared to traditional anthracycline use
Longer infusion times demonstrated a decrease in cardiotoxic effects without compromising efficacy
Histopathological assessment remains the most reliable method to gauge myocardial damage and monitor treatment outcomes.

Structured PICO

Do modified administration schedules, cardioprotective agents, or liposomal delivery reduce anthracycline-induced cardiotoxicity in patients receiving chemotherapy?

P

Population

Patients (adults and children) receiving anthracyclines for haematological and oncological malignancies

I

Intervention

Methods of reducing anthracycline-induced cardiotoxicity (including modified mode of administration such as split dosing or prolonged infusions, cardioprotective agents, and liposomal delivery)

C

Comparator

Standard bolus dosing of anthracyclines

O

Outcome

Anthracycline-induced cardiotoxicity (including congestive cardiac failure and myocyte damage)safety

Modifying anthracycline administration to reduce peak plasma levels, such as through split dosing or prolonged infusions, is an effective strategy to mitigate cardiotoxicity.

Limitations

Clinical research with larger numbers of patients needs to be performed in randomized trials.
Results cannot necessarily be extrapolated between different anthracycline drugs.
Non-invasive methods of detecting early cardiac damage that correlate with late outcomes need to be developed.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Modified dosing or agents may be considered to limit anthracycline cardiotoxicity; review leaves open comparative efficacy in current regimens.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Gill Levitt (1999) conducted a review in Anthracycline-induced cardiotoxicity. Cardioprotective strategies (scheduling, cardioprotective agents, liposomal delivery) was evaluated.

synapsesocial.com/papers/6a203697d976c11659b5d026 https://doi.org/10.1046/j.1365-2141.1999.01544.x

View at Publisher

Ask AI

Bookmark

Share

Cardioprotection

Key Points

Structured PICO

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Cardioprotection

Key Points

Structured PICO

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading